An interventional study of Audiometry in Hearing Loss, Conductive and Hearing Loss, Mixed, sponsored by Oticon Medical. Completed at 1 site in Denmark. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Oticon Medical · Not applicable, Interventional, and Other
The study is a combined retrospective (fitting visit) and prospective (study visit), multi-center, single arm study The study is part of the Post Market Clinical Follow (PMCF) activity. The investigational device used in this study is the Ponto 4 already fitted to the subjects prior to the study. The device is CE marked and available on the market since June 2019.
Treatment is not provided in the study therefore risks are limited to the audiological measurements. The audiological measurements in the study are standard non-invasive measurements already familiar to the clinics.
The hearing with Ponto 4 will be evaluated via speech and hearing tests, and patient reported outcomes.
This is a post market clinical follow up (PMCF) study with the purpose of gather knowledge on the use and performance of the Ponto 4 device on existing Ponto 4 users. The study does not include any treatment or fitting of new devices, instead the real-life application of the use of Ponto 4 on subjects already using Ponto 4(s) are investigated.
The Investigational Device used in the study is Ponto 4, a CE marked, and FDA cleared bone anchored hearing solution, produced by Oticon Medical AB and commercially available since June 2019.
The recruitment for this clinical investigation will be performed among subjects who have already received a Ponto 4 device as a minimum 1.5 month prior to the study. 20 patients, including minors down to 12 years old, with a conductive, mixed hearing loss or single-sided deafness will be included. The rationale for including minors is that they are also users of the device, and it is found important to collect data from their experience of using the device as well.
The study is a retrospective and prospective, multi-center study. It has one visit of 2,5-3 hours for adult subjects ≥18 years old. To minimize the burden and risks of tiredness for the minor subjects from 12-17 years old, the protocol activities can be divided into two visits. The decision will be based on the Investigators discretion.
The majority of the objectives of the study are prospectively collected whereas the BC In-situ (hearing with the Ponto 4 on) and audiometric data from the time of the fitting of Ponto 4, are collected retrospectively from the time of the fitting of Ponto 4 (aka the fitting visit).
The overall objectives of the study are to investigate the improvement in hearing with the Ponto 4(s) on the implanted ear(s), in terms of the subject's ability to hear sounds and understand speech when using the device.
The primary endpoint is to investigate the improvement in hearing with the Ponto 4(s) on the implanted ear for patients within intended use.
These will be evaluated through a hearing and a speech test, both assessing the hearing with the Ponto 4(s) both on and off. Additionally, the subject will complete 2 patient reported outcome, report daily usage time of the device and assess satisfaction of connectivity devices.
Minimal risks are expected for subjects participating in the study. Treatment is not provided in the study therefore risks are limited to the audiological measurements. The audiological measurements in the study are standard non-invasive measurements already familiar to the clinics. The measurements will require an extra effort and may be found slightly tiring by the subject. To mitigate the risk of tiredness the subject will be given the opportunity to have breaks during the visit.
82 studies on the registry are indexed under Hearing Loss, Conductive; 15 are open to participants now.
This study's enrollment of 20 is below the median of 30 across 59 interventional studies indexed under Hearing Loss, Conductive.
Browse Hearing Loss, Conductive studies →Oticon Medical is the lead sponsor of 45 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Asessments for the hearing with Ponto 4 sound processor on the implanted ear(s).
Device: Audiometry
Audiometry: Thresholds from the audiogram obtained when Ponto 4 were fitted. Pure tone air conduction (AC) and bone conduction (BC) audiometry conducted at the visit. Speech recognition in quiet: Speech intelligibility is measured in a soundproof room using the Matrix sentences presented from a loudspeaker. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. This test will be obtained both unaided and aided (with and without the Ponto 4(s)). Sound field Audiometry: Detection of sound field thresholds presented from a loudspeaker. Thresholds will be obtained both unaided and aided and the test order will be balanced between subjects. During these measurements, the Ponto 4 will be programmed in omni-directional mode, with noise reduction and feedback management system turned off.
Also known as: Speach recognition in quiet, Sound field audiometry, Patient reported outcomes
To Investigate the Improvement in Hearing With the Ponto 4 (s) on the Implanted Ear for Patients Within Intended Use.
Functional gain with Ponto 4, i.e. the difference between average unaided and aided sound field thresholds. The functional gain (PTA4) is calculated as the average of frequencies 500, 1000, 2000 and 4000 Hz.
Time frame: The outcome measure was assessed during Study Visit 1 (Day 1).
B. To Assess the Improvement of Hearing With the Ponto 4 on the Implanted Ear(s).
1\. Functional gain with Ponto 4, i.e. the difference between unaided and aided sound field thresholds, for frequencies 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz.
Time frame: The outcome measure was assessed during Study Visit 1 (Day 1).
C. To Assess the Improvement of Speech Recognition With Ponto 4 on the Implanted Ear(s).
Difference in speech recognition score in percent between unaided and aided, assessed in quiet. Speech recognition was measured in free field using the Matrix sentences test. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A formula selects a word from a category (name, verb, number, adjective and noun) and creates a five-word sentence. A word from each category is chosen at random to create the sentence. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. Speech was presented from a loudspeaker 1 meter in front of the subject (0 degree azimuth). The speech signal was fixed at 65 dB SPL (C-weighted). The subject had to repeat as many words as possible after each sentence. For the aided condition, Ponto 4 was tested in the subject's user settings. The test order of aided and unaided condition was balanced across subjects.
Time frame: The outcome measure was assessed during Study Visit 1 (Day 1).
G. To Assess the Degree to Which the Ponto 4 Compensates for the BC Hearing Loss on the Implanted Ear(s).
1\. Effective gain defined as the difference in dB between aided sound field thresholds with Ponto 4, and BC In-situ thresholds on the aided ear(s) measured at the time of the fitting of Ponto 4(s). The effective gain is calculated for frequencies 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz.
Time frame: The assessment for this outcome measure was based on the BC in situ test conducted during a visit at least 6 weeks prior to Study Visit 1 (data collected retrospectively), and an aided sound field thresholds test conducted on Study Visit Day 1.
H. To Evaluate the Above Objectives on Individual Levels
Endpoints A1, B1, C1 analyzed as the proportion of subjects whose performance improved or remained the same (difference ≥ 0) in unaided to aided comparisons.
Time frame: The outcome measure was assessed during Study Visit 1 (Day 1).
I. To Assess the Degree of Inner Ear Hearing Loss Degradation on the Implanted Ear(s) (for SSD the Stimulated Ear).
1\. Hearing loss degradation is the difference in dB between masked (if not available unmasked) BC thresholds obtained at the study visit, and at the visit when Ponto 4(s) was fitted. Hearing loss degradation for subjects with MHL/CHL is the difference in dB between masked (if not available, then unmasked) BC thresholds obtained at the study visit and at the visit when the Ponto 4(s) was fitted. For subjects with SSD, AC thresholds on the non-implanted ear were used for this calculation.
Time frame: Fitting Visit (at least 6 weeks prior to Study Visit 1 - data retrospectively collected) and Study Visit 1 (Day 1).
J. To Assess if a Patient's With CHL/MHL Hearing Loss Has Degraded to Being Outside Fitting Range on the Implanted Ear(s).
1\. BC hearing loss (PTA4), measured at the study visit, being outside intended fitting range (PTA4 \>45 dB HL) compared to being inside fitting range (PTA\<45 dB HL) at the time of the study visit.
Time frame: fitting visit ≥6 weeks prior to study visit
K. To Asses if Patients' With CHL/MHL Air to Bone Gap (PTA4) Has Increased/Decreased on the Implanted Ear(s)
1\. The difference between masked (if not available unmasked) BC and AC thresholds, denoted 'air to bone gap', calculated for frequencies 500, 1000, 2000 and 4000 Hz from audiogram measured at the study visit and the fitting visit.
Time frame: Fitting Visit (at least 6 weeks prior to Study Visit 1 - data retrospectively collected) and Study Visit 1 (Day 1).
L. To Assess the Usage and Performance of Connectivity Device(s)
1\. Questionnaire: Self-reported satisfaction ratings 0-10, for connectivity device(s) previously given to the test subject, where 0 is "very unsatisfied" and 10 is "very satisfied".
Time frame: Visit 1, Day 1
F. To Assess the Usage Time With Ponto 4.
Questionnaire: Self-reported usage hours per day during the month prior to the study visit across all subjects.
Time frame: Visit 1, Day 1
E. To Assess the Quality of Life of the Ponto 4
GHSI Questionnaire: Scores across all subjects, on a scale from 0 to 100, with a higher score indicating a better quality of life.
Time frame: Visit 1, Day 1 (For minors: Can be performed at a Visit 2, week 2, +/- 1 week)
D. To Assess the Subjective Experience of the Ponto 4
SSQ Questionnaire: Scores across all subjects, on a subjective scale from 0-10, where 0 is "the worst" and 10 is "the best"
Time frame: Visit 1,Day 1 (For minors: Can be performed at a Visit 2, week 2, +/- 1 week)
| Milestone | Ponto 4 Sound Processor Users |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
Functional gain with Ponto 4, i.e. the difference between average unaided and aided sound field thresholds. The functional gain (PTA4) is calculated as the average of frequencies 500, 1000, 2000 and 4000 Hz.
| [dB] | Ponto 4 Sound Processor Users |
|---|---|
| To Investigate the Improvement in Hearing With the Ponto 4 (s) on the Implanted Ear for Patients Within Intended Use. | 31.5 ± 9.5 |
1\. Functional gain with Ponto 4, i.e. the difference between unaided and aided sound field thresholds, for frequencies 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz.
| [dB] | Ponto 4 Sound Processor Users |
|---|---|
| 250Hz | 14.2 ± 9.9 |
| 500Hz | 28.7 ± 12.0 |
| 1000Hz | 36.6 ± 9.9 |
| 2000Hz | 28.6 ± 13.8 |
| 3000Hz | 32.9 ± 11.6 |
| 4000Hz | 32.8 ± 8.6 |
| 6000Hz | 22.7 ± 10.2 |
| 8000Hz | 22.1 ± 12.3 |
Difference in speech recognition score in percent between unaided and aided, assessed in quiet. Speech recognition was measured in free field using the Matrix sentences test. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A formula selects a word from a category (name, verb, number, adjective and noun) and creates a five-word sentence. A word from each category is chosen at random to create the sentence. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. Speech was presented from a loudspeaker 1 meter in front of the subject (0 degree azimuth). The speech signal was fixed at 65 dB SPL (C-weighted). The subject had to repeat as many words as possible after each sentence. For the aided condition, Ponto 4 was tested in the subject's user settings. The test order of aided and unaided condition was balanced across subjects.
| percentage points (% points) | Ponto 4 Sound Processor Users |
|---|---|
| C. To Assess the Improvement of Speech Recognition With Ponto 4 on the Implanted Ear(s). | 55.9 ± 31.7 |
1\. Effective gain defined as the difference in dB between aided sound field thresholds with Ponto 4, and BC In-situ thresholds on the aided ear(s) measured at the time of the fitting of Ponto 4(s). The effective gain is calculated for frequencies 250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz.
| dB | Ponto 4 Sound Processor Users |
|---|---|
| 250Hz | 22.0 ± 7.3 |
| 500Hz | 7.14 ± 7.84 |
| 1000Hz | 3.21 ± 7.69 |
| 2000Hz | 2.86 ± 8.25 |
| 3000Hz | 10.20 ± 7.0 |
| 4000Hz | 13.8 ± 7.1 |
| 6000Hz | 17.0 ± 9.4 |
| 8000Hz | 12.3 ± 9.7 |
Endpoints A1, B1, C1 analyzed as the proportion of subjects whose performance improved or remained the same (difference ≥ 0) in unaided to aided comparisons.
| Percentage of participants (%) | Ponto 4 Sound Processor Users |
|---|---|
| PTA4 unaided to aided condition | 100 |
| All individual frequencies unaided to aided condition | 100 |
| Speech recognition scores unaided to aided condition | 100 |
1\. Hearing loss degradation is the difference in dB between masked (if not available unmasked) BC thresholds obtained at the study visit, and at the visit when Ponto 4(s) was fitted. Hearing loss degradation for subjects with MHL/CHL is the difference in dB between masked (if not available, then unmasked) BC thresholds obtained at the study visit and at the visit when the Ponto 4(s) was fitted. For subjects with SSD, AC thresholds on the non-implanted ear were used for this calculation.
| dB | Ponto 4 Sound Processor Users |
|---|---|
| MHL/CHL | 0.114 ± 5.761 |
| SSD | 1.75 ± 2.88 |
1\. BC hearing loss (PTA4), measured at the study visit, being outside intended fitting range (PTA4 \>45 dB HL) compared to being inside fitting range (PTA\<45 dB HL) at the time of the study visit.
Results for this outcome have not been posted.
1\. The difference between masked (if not available unmasked) BC and AC thresholds, denoted 'air to bone gap', calculated for frequencies 500, 1000, 2000 and 4000 Hz from audiogram measured at the study visit and the fitting visit.
| dB | Ponto 4 Sound Processor Users |
|---|---|
| Fitting visit | 45.8 ± 13.6 |
| Study visit | 50.2 ± 15.2 |
1\. Questionnaire: Self-reported satisfaction ratings 0-10, for connectivity device(s) previously given to the test subject, where 0 is "very unsatisfied" and 10 is "very satisfied".
| units on a scale | Ponto 4 Sound Processor Users |
|---|---|
| On App | 8.21 ± 2.10 |
| Connect Clip | 6.90 ± 2.30 |
| Remote Control | 8.00 ± 2.35 |
| Edu Mic | 9.00 ± 0.00 |
Questionnaire: Self-reported usage hours per day during the month prior to the study visit across all subjects.
| average hours/day | Ponto 4 Sound Processor Users |
|---|---|
| F. To Assess the Usage Time With Ponto 4. | 12.6 ± 5.2 |
GHSI Questionnaire: Scores across all subjects, on a scale from 0 to 100, with a higher score indicating a better quality of life.
| units on a scale | Single Arm |
|---|---|
| E. To Assess the Quality of Life of the Ponto 4 | 65.4 ± 11.7 |
SSQ Questionnaire: Scores across all subjects, on a subjective scale from 0-10, where 0 is "the worst" and 10 is "the best"
| units on a scale | Single Arm |
|---|---|
| D. To Assess the Subjective Experience of the Ponto 4 | 6.28 ± 1.91 |
Collected over study duration was one, approximately 2 hour long, visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ponto 4 Sound Processor Users | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Age, Categorical(Participants) | Ponto 4 Sound Processor Users |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 13 |
| >=65 years | 7 |
| Age, Continuous(years) | Ponto 4 Sound Processor Users |
|---|---|
| Mean | 56.1 ± 17.6 |
| Sex: Female, Male(Participants) | Ponto 4 Sound Processor Users |
|---|---|
| Female | 9 |
| Male | 11 |
| Race and Ethnicity Not Collected(Participants) | Ponto 4 Sound Processor Users |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.